-
公开(公告)号：EP2780337A1
公开(公告)日：2014-09-24
申请号：EP12849788.0
申请日：2012-11-09
发明人： EDMONDSON, Scott , HU, Zhiyong , LIU, Ping , MORRIELLO, Gregori, J. , SZEWCZYK, Jason, W. , WANG, Bowei , WOOD, Harold, B. , ZHU, Cheng , ZHU, Yuping , GUO, Zhiqiang
IPC分类号： C07D401/00
CPC分类号： C07D513/04 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04
摘要： Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included
-
2.发明公开SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT 有权取代的环丙基化合物，含有这些化合物的组合物和治疗方法
公开(公告)号：EP2693882A1
公开(公告)日：2014-02-12
申请号：EP12767881.1
申请日：2012-04-05
发明人： EDMONDSON, Scott , GUO, Zhiqiang , GEISS, William, B. , WOOD, Harold, B. , STAMFORD, Andrew, W. , MILLER, Michael, W. , DEMONG, Duane, E. , MORRIELLO, Gregori, J. , ANAND, Rajan , COLANDREA, Vincent, J. , MACALA, Megan , MALETIC, Milana , ZHU, Cheng , ZHU, Yuping , SUN, Wanying , ZHAO, Kake , HUANG, Yong , HARRIS, Joel, M. , CHANG, Lehua , KAR, Nam Fung , HU, Zhiyong , WANG, Liping , WANG, Bowei , LIU, Ping , SZEWCZYK, Jason, W.
IPC分类号： A01N43/54 , A61K31/505 , A01N43/40 , A61K31/445
CPC分类号： C07D513/04 , A61K9/4858 , C07D211/22 , C07D401/12 , C07D405/04 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04
摘要： Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included
摘要翻译： 公开的式I的取代环丙基化合物及其药学上可接受的盐公开用于治疗或预防2型糖尿病和类似病症。 该化合物可用作G蛋白偶联受体GPR-119的激动剂。 药物组合物和治疗方法也包括在内
-
公开(公告)号：EP3974413A1
公开(公告)日：2022-03-30
申请号：EP21202075.4
申请日：2014-12-17
发明人： HAGMANN, William K. , LI, Bing , SZEWCZYK, Jason, W. , WANG, Bowei , PARKER, Dann , BLIZZARD, Timothy , JOSIEN, Hubert , BIJU, Purakkattle , CHOBANIAN, Harry , GUDE, Candido , NARGUND, Ravi, P. , PIO, Barbara , DANG, Qun , LIN, Linus, S. , HU, Bin , CUI, Mingxiang , CHEN, Zhengxia , DAI, Meibi , ZHANG, Zaihong , LV, Ying , TIAN, Lili
IPC分类号： C07D213/64 , C07D213/74 , C07D221/20 , C07D239/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/04 , C07D451/06 , C07D471/04 , C07D493/04 , A61K31/437 , A61K31/438 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/4545 , A61K31/505
摘要： The present invention relates to a compound represented by formula I:
and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.-
公开(公告)号：EP1893608B1
公开(公告)日：2011-08-17
申请号：EP05858618.1
申请日：2005-10-06
发明人： COSFORD, Nicholas, D. , SEIDERS, Thomas, J. , PAYNE, Joseph , ROPPE, Jeffrey, R. , HUANG, Dehua , SMITH, Nicholas, D. , POON, Steve, F. , KING, Chris , EASTMAN, Brian, W. , WANG, Bowei , ARRUDA, Jeannie, M. , VERNIER, Jean-Michel , ZHAO, Xiumin
IPC分类号： C07D417/06 , C07D417/14 , C07D417/04 , A61K31/4439 , A61P25/00
CPC分类号： C07D417/06 , C07D417/14 , C07D471/04
摘要： The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.
-
公开(公告)号：EP2780337B1
公开(公告)日：2017-12-20
申请号：EP12849788.0
申请日：2012-11-09
发明人： EDMONDSON, Scott , HU, Zhiyong , LIU, Ping , MORRIELLO, Gregori, J. , SZEWCZYK, Jason, W. , WANG, Bowei , WOOD, Harold, B. , ZHU, Cheng , ZHU, Yuping , GUO, Zhiqiang
IPC分类号： C07D401/00
CPC分类号： C07D513/04 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04
摘要： Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.
-
6.发明授权SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT 有权取代的环丙基化合物，含有这些化合物的组合物和治疗方法
公开(公告)号：EP2693882B1
公开(公告)日：2017-06-28
申请号：EP12767881.1
申请日：2012-04-05
发明人： EDMONDSON, Scott , GUO, Zhiqiang , GEISS, William, B. , WOOD, Harold, B. , STAMFORD, Andrew, W. , MILLER, Michael, W. , DEMONG, Duane, E. , MORRIELLO, Gregori, J. , ANAND, Rajan , COLANDREA, Vincent, J. , MACALA, Megan , MALETIC, Milana , ZHU, Cheng , ZHU, Yuping , SUN, Wanying , ZHAO, Kake , HUANG, Yong , HARRIS, Joel, M. , CHANG, Lehua , KAR, Nam Fung , HU, Zhiyong , WANG, Liping , WANG, Bowei , LIU, Ping , SZEWCZYK, Jason, W.
IPC分类号： C07D211/22 , C07D401/12 , C07D405/04 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04 , C07D513/04 , A61K31/506 , A61P5/50
CPC分类号： C07D513/04 , A61K9/4858 , C07D211/22 , C07D401/12 , C07D405/04 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04
-
公开(公告)号：EP3082786A1
公开(公告)日：2016-10-26
申请号：EP14870903.3
申请日：2014-12-17
发明人： HAGMANN, William, K. , LI, Bing , SZEWCZYK, Jason, W. , WANG, Bowei , PARKER, Dann , BLIZZARD, Timothy , JOSIEN, Hubert , BIJU, Purakkattle , CHOBANIAN, Harry , GUDE, Candido , NARGUND, Ravi, P. , PIO, Barbara , DANG, Qun , LIN, Linus, S. , HU, Bin , CUI, Mingxiang , CHEN, Zhengxia , DAI, Meibi , ZHANG, Zaihong , LV, Ying , TIAN, Lili
IPC分类号： A61K31/192 , A61K31/381
CPC分类号： C07D493/04 , A61K31/437 , A61K31/438 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/4545 , A61K31/46 , A61K31/505 , A61K31/506 , A61K45/06 , C07D213/64 , C07D213/74 , C07D221/20 , C07D239/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/04 , C07D451/06 , C07D471/04
摘要： The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.023 秒)
